ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma

Xiao, Zhijun; Li, Jinyin; Yu, Qian; Zhou, Ting; Duan, Jingjing; Yang, Zhen; Liu, Cuicui*; Xu, Feng*南方医科大学; 上海大学; 6
Frontiers in Pharmacology2021-12-23DOI: 10.3389/fphar.2021.778294
12被引8阅读
引用收藏
分享

摘要

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors with an extremely low 5-year survival rate. Accumulating evidence has unveiled that inflammatory response promotes tumor progression, enhances angiogenesis, and causes local immunosuppression. Herein, we aim to develop an inflammatory related prognostic signature, and found it could be used to predict gemcitabine response in PDAC.Methods: PDAC cohorts with mRNA expression profiles and clinical information were systematically collected from the four public databases. An inflammatory response related genes (IRRGs) prognostic signature was constructed by LASSO regression analysis. Kaplan-Meier survival analysis, receiver operating characteristic analysis, principal component analysis, and univariate and multivariate Cox analyses were carried out to evaluate effectiveness, and reliability of the signature. The correlation between gemcitabine response and risk score was evaluated in the TCGA-PAAD cohort. The GDSC database, pRRophetic algorithm, and connectivity map analysis were used to predict gemcitabine sensitivity and identify potential drugs for the treatment of PDAC. Finally, we analyzed differences in frequencies of gene mutations, infiltration of immune cells, as well as biological functions between different subgroups divided by the prognostic signature.Results: We established a seven IRRGs (ADM, DCBLD2, EREG, ITGA5, MIF, TREM1, and BTG2) signature which divided the PDAC patients into low- and high-risk groups. Prognostic value of the signature was validated in 11 PDAC cohorts consisting of 1337 PDAC patients from 6 countries. A nomogram that integrated the IRRGs signature and clinicopathologic factors of PDAC patients was constructed. The risk score showed positive correlation with gemcitabine resistance. Two drugs (BMS-536924 and dasatinib) might have potential therapeutic implications in high-risk PDAC patients. We found that the high-risk group had higher frequencies of KRAS, TP53, and CDKN2A mutations, increased infiltration of macrophages M0, neutrophils, and macrophages M2 cells, as well as upregulated hypoxia and glycolysis pathways, while the low-risk group had increased infiltration of CD8(+) T, naive B, and plasma and macrophages M1 cells.Conclusion: We constructed and validated an IRRGs signature that could be used to predict the prognosis and gemcitabine response of patients with PDAC, as well as two drugs (BMS-536924 and dasatinib) may contribute to PDAC treatment.

学科与关键词

关键词
pancreatic ductal adenocarcinomainflammatory responsegene signaturetumor microenvironmentgemcitabine responsegene mutation
相关
加载中…
  • Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
    Liu, Kaidong; Geng, Yiding; Wang, Linzhu; Xu, Huanhuan; Zou, Min; Li, Yawei; Zhao, Zhangxiang; Chen, Tingting; Xu, Fengyan; Sun, Liang; Wu, Shuliang*; Gu, Yunyan*Molecular Oncology, 2022, 16(16): 3034-3051.被引 8
  • Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma
    Li, Shuanghua*; Chen, Rui*; Luo, Wang; Lin, Jinyu; Chen, Yunlong; Wang, Zhuangxiong; Lin, Wenjun; Li, Baihong; Wang, Junfeng; Yang, JianCOMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2022, 25(12): 2070-2081.被引 1
  • A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer
    Xiao, Mingjia; Liang, Xiangjing; Yan, Zhengming; Chen, Jingyang; Zhu, Yaru; Xie, Yuan; Li, Yang; Li, Xinming; Gao, Qingxiang; Feng, Feiling*; Fu, Gongbo*; Gao, Yi*Frontiers in Immunology, 2022, 13: 803962.被引 13
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2021-12-23
卷期
第 12 卷
页码
778294
DOI
10.3389/fphar.2021.778294
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE

作者

  • X

    Xiao, Zhijun (第一作者)

    6 · shanghai univ

  • L

    Li, Jinyin

    xuhui cent hosp

查看全部 8 位作者收起作者
  • Y

    Yu, Qian

  • Z

    Zhou, Ting

    6 · shanghai univ

  • D

    Duan, Jingjing

    6 · shanghai univ

  • Y

    Yang, Zhen

    6 · shanghai univ

  • L

    Liu, Cuicui (通讯)

    6 · shanghai univ

  • X

    Xu, Feng (通讯)

    6 · shanghai univ · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417